Alkermes to Present Clinical Data related to Schizophrenia and Depression at American Psychiatric Association Annual Meeting


Alkermes plc (Nasdaq: ALKS) announced the presentation of six posters highlighting data from the company’s schizophrenia and depression portfolios at the 2018 American Psychiatric Association (APA) Annual Meeting in New York, May 5-9, 2018.

“Alkermes is pleased to present this important research as a continuation of our commitment to developing novel medicines in areas of significant unmet medical need,” stated Craig Hopkinson, M.D., Chief Medical Officer and Senior Vice President of Medicines Development and Medical Affairs at Alkermes. “Our clinical and research programs continue to advance and we look forward to multiple potential catalysts across our CNS portfolio in the years ahead.”

Key presentation highlights include:

  • Results from a pharmacokinetic and safety study evaluating Aripiprazole Lauroxil NanoCrystal® Dispersion (ALNCD), a novel, investigational product designed for initiation onto ARISTADA®
  • Patient preferences concerning the efficacy and side-effect profile, including weight gain, of antipsychotic medications for the treatment of schizophrenia
  • Results from an open-label, phase 3 study in patients with major depressive disorder (MDD) assessing long-term efficacy, safety and tolerability of ALKS 5461

A full list of the Alkermes presentations at APA follows:


  • Poster #P6-142: “Aripiprazole Lauroxil NanoCrystal® Dispersion: A Potential One-Day Initiation Regimen for Long-Acting Aripiprazole Lauroxil,” on Monday, May 7, 2018, 2:00 – 4:00 p.m. ET
  • Poster #P6-146: “Patient Preferences Concerning the Efficacy and Side-Effect Profile of Schizophrenia Medication: A Survey of Patients Living With Schizophrenia,” on Monday, May 7, 2018, 2:00 – 4:00 p.m. ET
  • Poster #P6-149: “Schizophrenia Complicated by Comorbid Alcohol Use Disorder: Symptom Outcomes From a Phase 2 Randomized Controlled Trial,” on Monday, May 7, 2018, 2:00 – 4:00 p.m. ET
  • Poster #P6-159: “Translating Trial Endpoints to NNT, NNH, and LHH: A Re-Analysis of the Pivotal Trial of Aripiprazole Lauroxil for the Treatment of Schizophrenia,” on Monday, May 7, 2018, 2:00 – 4:00 p.m. ET
  • Poster #P8-169: “A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients With Acute Exacerbation of Schizophrenia,” on Tuesday, May 8, 2018, 2:00 – 4:00 p.m. ET

Major Depressive Disorder

  • Poster #P8-048: “Long-Term Efficacy, Safety and Tolerability of Adjunctive ALKS 5461 in Patients With Major Depressive Disorder Enrolled in a Phase 3 Study,” on Tuesday, May 8, 2018, 2:00 – 4:00 p.m. ET


About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Schizophrenia, visit


News Source: Alkermes Website

Image source: